Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence
Abstract Purpose Aromatase inhibitors (AIs) are associated with reduction in bone mineral density (BMD). The use of bone strengthening agents zoledronic acid and denosumab are associated with improved breast cancer outcomes for post‐menopausal patients treated with AIs. This study investigates wheth...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-01-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.6846 |